Extranodal marginal zone lymphoma of the dura mater with IgH/MALT1 translocation and review of literature

Abstract

Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma involving brain, intraocular structures and spinal cord, without evidence of systemic disease. The majority of PCNSLs are diffuse large B-cell type. We encountered a rare case of primary dural marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) with extension into the brain in a 59-year-old man. A magnetic resonance imaging scan showed a 22-mm tumor located in the left posterior temporal lobe extending from the dura. Histopathology revealed a lymphoplasmacytic infiltration of the dura and the brain parenchyma in a perivascular pattern. Immunohistochemical and in situ hybridization studies showed a B-cell phenotype with kappa light chain restriction. Fluorescent in situ hybridization study showed a t(14;18)(q32;q21) with immunoglobulin heavy-chain/MALT1 fusion. The molecular study for immunoglobulin heavy-chain gene rearrangement by polymerase chain reaction showed a clonal gene rearrangement.

Introduction

The majority of the central nervous system (CNS) lymphomas are due to the spread of a systemic lymphoma to the CNS [1, 2]. Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) that involves the brain, leptomeninges, intraocular structures, or spinal cord in the absence of systemic disease. It occurs in both immunocompromised and immunocompetent patients and accounts for 2.7% of all malignant diseases of the central nervous system [3]. The incidence of PCNSL has increased during the last three decades, and it occurs at a younger age in the immunocompromised patients.

According to World Health Organization classification [4], the majority of PCNSL are diffuse large B-cell lymphoma. T-cell (T-PCNSL), low grade B-cell lymphomas, and anaplastic large cell lymphoma of the CNS are extremely rare [5, 6]. The PCNSL in human immunodeficiency virus positive patients is almost always associated with the Epstein–Barr virus (EBV), while the association of EBV in immunocompetent patients is rare [7].

The majority of PCNSL presents as a space-occupying lesion within the brain parenchyma and periventricular regions. Primary dural CNS lymphomas are extremely rare. The majority of them are low grade NHL, with marginal zone B-cell lymphoma being the most common. There are only a handful of case reports and a small case series which describe the dural involvement [8–10]. In the present study, we describe the clinical, histopathological, immunohistochemical, cytogenetic, and molecular findings of a case of primary extranodal marginal zone lymphoma involving the dura with extension to the brain parenchyma in an immunocompetent patient. This is the first report of a primary dural marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type that has shown a molecular rearrangement of t(14;18)(q32;q21) involving the MALT1gene.

Material and methods

All available routine hematoxylin and eosin, immunohistochemical, and in situ hybridization slides of formalin-fixed paraffin-embedded tissue from a diagnostic biopsy of the patient were reviewed. Working antibody source, clone, and dilution are listed in Table 1. Staining was performed on an automated immunostainer (Ventana Medical Systems, Tuscon, AZ and Dako, Carpentaria, CA, USA). For in situ hybridization (ISH), slides were deparaffinized and antigen retrieval was performed by a Ventana’s proprietary protease-1 treatment. Subsequently, the slides were incubated with undiluted Kappa, Lambda, and EBV probe solutions from Ventana.

Table 1.

Panel of antibodies

Antibody to	Clone	Company	Dilution
CD20	L26	Dakoa	1:500
CD79a	JCB117	Dako	1:80
CD3	F7.2.38	Dako	Neat
CD5	SP19	Ventanab	Neat
Cyclin D1	SP4	Ventana	1:100
CD21	1F8	Dako	1:80
Ig G	A57H	Dako	1:200
Ig M	R1/69	Dako	1:200
CD10	56C6	Ventana	Neat

^aDako, Carpenteria, CA, USA

^bVentana, Tucson, AZ, USA

Fluorescent in situ hybridization

Fluorescence in situ hybridization (FISH) was performed on 4–5-μm unstained paraffin-embedded tissue sections using the LSI immunoglobulin heavy-chain (IgH)/MALT1 dual-fusion translocation probe and the LSI BCL6 (3q27) dual-color break-apart probe obtained from Vysis/Abbott, Inc. (Downer’s Grove, IL, USA). Prior to hybridization, the slides were pretreated by utilizing the VP 2000 automated slide processor (Vysis/Abbott, Inc.) following a modified version of the manufacturer’s recommended protocol. Codenaturation of the DNA probe and the tissue DNA was performed on a HYBrite^™ instrument (Vysis/Abbott, Inc., IL, USA) at 80°C for 5 min, followed by an overnight hybridization at 37°C, postwashed in 2× SSC/0.3% NP-40 at 73°C for 2 min, and counterstained with 4′,6-diamidino-2-phenylindole II.

Molecular diagnostics

Immunoglobulin heavy-chain gene rearrangements were analyzed by using the InVivoScribe IgH framework III/heavy-chain joining (JH) assay, according to the manufacturer’s protocol (InVivoScribe Technologies, San Diego, CA, USA). Framework II/JH segments were amplified using the forward (5′ TGG RTC CGM CAG SCY YCN GG 3′) and reverse (5′ 6-FAM ACC TGA GGA GAC GGT GAC C 3′) primers as previously described [11]. Polymerase chain reaction (PCR) products were analyzed using a capillary electrophoresis as described previously [12].

Case report

The patient was a 59-year-old gentleman, who presented with speech difficulties, right-sided numbness, and episodes of unusual smell for 8 months. He did not have a history of headache, seizures, and inflammatory conditions. A magnetic resonance imaging scan showed a heterogeneously enhancing 22-mm tumor located in the left posterior temporal lobe abutting the dura. Subsequently, he underwent left temporal craniotomy and microsurgical resection of the tumor. The patient underwent computed tomography scans of the chest, abdomen, and pelvis (staging), with normal findings. Bone marrow aspiration and biopsy examinations did not reveal any evidence of lymphoma. A work-up for monoclonal gammopathy including serum protein electrophoresis and serum level of immunoglobulin A, G, and M showed normal results.

Results

The histopathology of the tumor showed a prominent lymphoplasmacytic infiltration in the brain parenchyma and the overlying fibrous (dura) tissue. The tumor showed a characteristic, angiocentric pattern, forming cuffs of tumor cells around the cerebral blood vessels (Virchow–Robin space; Fig. 1A,B). Most of the lymphocytes were small with condensed chromatin in a round to slightly irregular nucleus and a scant to moderate amount of pale cytoplasm. A prominent plasma cell population was present. Reactive lymphoid follicles were not identified.

Fig. 1.

Morphologic, immunohistochemical, Ig light chain expression and FISH assay of the PCNS MALT lymphoma. A and B Histopathology of the lymphoma showing a prominent lymphoplasmacytic infiltration with a characteristic perivascular pattern (hematoxylin–eosin, original magnification, ×100 and ×400). C and D Many of the lymphoma cells were positive for CD 20 and CD 79a (immunohistochemistry ×100). E In situ hybridization showing the tumor cells are kappa light chain restricted (×100). F In situ hybridization showing the tumor cells are lambda light chain negative (×100). G FISH analysis showing the interphase cells with IGH/MALT1 rearrangement indicated by two fusion signals (juxtaposed green and red signal). The normal IgH and MALT1 loci are represented by the single red and single green signals respectively (×100)

Immunohistochemical studies showed that the tumor cells were positive for B-cells markers (cluster of differentiation (CD) 20, CD79a; Fig. 1C,D). The neoplastic plasma cells were monoclonal for Ig G and kappa light chain (Fig. 1E), and negative for lambda light chain (Fig. 1F). The tumor cells were immunonegative for CD3, CD5, cyclin D1, CD21, CD23, CD10, and Ig M. EBV testing by ISH (EBV-encoded small RNA) was negative. The FISH study for MALT1 translocations showed a rearrangement of the MALT1 region at 18q21 in 30% of the interphase cells. Subsequent studies showed fusion of IgH/MALT1 in 74% of the cells (Fig. 1G). Additional studies for trisomy 3 and 7 were negative. The molecular study for IgH rearrangement by PCR showed a single peak indicating clonal immunoglobulin heavy-chain gene rearrangement using the primers for heavy-chain variable (VH; framework II) and JH regions (Fig. 2). The tumor was negative for clonal IgH gene by PCR using the primers to VH framework III and JH regions. The staging evaluation was negative for systemic involvement by lymphoma.

Fig. 2.

Immunoglobulin heavy-chain gene rearrangement study—PCR product analyzed by capillary electrophoresis showing a clonal rearrangement. X axis length of amplicon, Y axis intensity of signal

Discussion

Isaacson and Wright were the first to describe the marginal zone B-cell lymphoma (MZL) in mucosa-associated lymphoid tissue of the gastrointestinal tract in 1983 [13]. Depending on the site of involvement, the MZL is classified into three subtypes: (1) splenic MZL, (2) nodal MZL, and (3) extranodal MZL of the mucosa-associated lymphoid tissues type [14, 15].

Among the MALT lymphomas, the gastrointestinal tract and lungs are the most common sites [16]. It is also recognized in salivary glands, skin, thyroid, lung, ocular adnexa, liver, CNS, and breast [17]. MALT lymphoma of the CNS is extremely rare. Dural MALT lymphoma is the most common site of involvement in the CNS with a rare occurrence in the lateral ventricle [18, 19].

To date, 39 cases of primary dural MALT lymphomas have been reported in the literature (Table 2). They usually occur in the middle-aged to elderly women and present with headache, seizures, and visual disturbance [18]. Although CNS is devoid of mucosal tissue, it has been hypothesized that the meningothelial cells serve as a substitute for the mucosal surface in MALT lymphoma of the CNS [20, 21].

Table 2.

Clinicopathological features of the reported cases of primary central nervous system lymphoma of mucosa-associated lymphoid tissue type

Case	Reference	Location of dura	Presenting symptoms	Age (years)	Sex	Preexisting condition	Treatment	FISH studies	IgH studies	Follow up (months)	Status
1	Kumar et al. [21]	Cavernous sinus	Numbness and visual field defects	40	F	None	RT	ND	ND	63	CR1
2	Kumar et al. [21]	Biparietal	Seizures	62	F	None	Chemo	ND	Mono	22	CR1
3	Kumar et al. [21]	Frontal	Seizures; numbness	52	F	None	RT and chemo	ND	Mono	7	CR1
4	Kumar et al. [21]	Tentorium	Headache, visual defect, numbness	43	F	None	RT	ND	Negative	9	CR1
5	Kumar et a1. [21]	Falx cerebri	Seizures	57	F	None	RT	ND	Mono	14	CR1
6	Kambham et al. [26]	Tentorium	Hearing loss, weakness	39	F	None	Resection	ND	Mono	48	AWD
7	Kambham et al. [26]	Frontoparietal	Headache, visual defect, numbness	62	F	None	Resection and RT	ND	Negative	6	AWD
8	Altundag et al. [27]	Parietal	Seizures	66	F	None	Resection	ND	ND	12	CR1
9	Itoh et al. [20]	Cerebellopontine	Tinnitus, headache	28	F	Sjogren's syndrome	Resection	ND	ND	24	CR1
10	Sanjeevi et al. [28]	Cavernous sinus	Headache, visual defect	46	F	Grave's disease	Resection and RT	ND	ND	15	CR1
11	Goetz et al. [29]	Frontoparietal	Hemiparesis	64	F	None	Resection and RT	ND	ND	3	CR1
12	Bodi et al. [30]	Frontal	Seizures, dizziness	56	F	None	Resection	ND	ND	18	CR1
13	Lehman et al. [31]	Falx cerebri	Seizures, speech defect	63	F	None	RT	ND	ND	8	AWD
14	Benouaich et al. [32]	Frontoparietal	Headache	38	F	None	RT and chemo	ND	ND	24	CR1
15	Benouaich et al. [32]	Temporal, parieto-occipital	Headache	45	F	None	RT and chemo	ND	ND	12	CR1
16	Kelly et al. [18]	Choroid plexus	Headache, seizures	53	M	None	Resection and RT	Negative	ND	12	CR1
17	Tu et al. [25]	Falx cerebri	NA	56	F	None	Not available	Tri 3	Negative	NA	NA
18	Tu et al. [25]	Frontal dura	Seizures	49	M	None	Chemo	Tri 3	Negative	90	CR1
19	Tu et al. [25]	Frontal dura	Seizures	66	M	None	RT	Tri 3	Negative	13	CR1
20	Tu et al. [25]	Posterior fossa	NA	55	F	None	NA	ND	Negative	NA	NA
21	Tu et al. [25]	Middle cranial fossa	NA	45	F	None	NA	ND	Negative	NA	NA
22	Tu et al [25]	NA	NA	68	F	None	NA	Tri 3	Negative	NA	NA
23	Tu et al. [25]	Subdural	NA	29	F	None	RT	Negative	Negative	36	CR1
24	Tu et al. [25]	Frontotemporal	Headache, drowsiness	61	F	None	NA	Negative	Negative	21	CR1
25	Tu et al. [25]	Occipital	Ataxia	62	F	None	RT	Tri 3, 7, 12, 18	Negative	25	CR1
26	Tu et al. [25]	Parietal	Facial drop, numbness, dysarthria	47	M	None	NA	ND	ND	NA	NA
27	Tu et al. [25]	Frontoparietal	Right arm pain	57	F	None	RT and chemo	Negative	Negative	65	CR1
28	Tu et al. [25]	Tentorium	Visual deficits	70	F	None	RT	Negative	Negative	45	CR1
29	Tu et al. [25]	Falx	Gait disturbance, visual deficits	59	F	None	RT	Negative	Negative	32	CR1
30	Tu et al. [25]	Suprasellar, sella	Headache, visual deficits	53	F	None	RT	Negative	Negative	11	CR1
31	Tu et al. [25]	Falx tentorium	Headache, ear pain	48	F	None	RT and chemo	Tri 3, 7, 12, 18	Negative	20	CR1
32	Iwamoto et al. [33]	Temporoparietal	Headache, facial weakness	64	F	None	Resection and chemo	ND	ND	78	CR1
33	Iwamoto et al. [33]	Frontotemporal	Seizures, visual defects	33	F	None	RT and chemo	ND	ND	84	CR1
34	Iwamoto et al. [33]	Tentorium, temporal	Headache, dizziness, numbness	35	M	None	RT and chemo	ND	ND	53	CR1
35	Iwamoto et al. [33]	Tentorium	Seizures	47	M	None	RT	ND	ND	27	CR1
36	Iwamoto et al. [33]	Frontal, sphenoidal	Visual deficits, paresthesias	39	F	None	RT	ND	ND	6	CR1
37	Iwamoto et al. [33]	Parietal	Seizures	49	F	None	RT	ND	ND	7	CR1
38	Iwamoto et al. [33]	Frontal	Headache	51	F	None	RT	ND	ND	8	CR1
39	Iwamoto et al. [33]	Frontal	Headache, visual deficits	50	F	None	RT	ND	ND	5	CR1
40	Bhagavathi et al. [present report]	Temporal	Altered speech, numbness	59	M	None	RT	t(14;18)(q32;q21)	Mono	1	AWD

M Male, F female RT radiotherapy, chemo chemotherapy, ND not done, CR complete remission, AWD alive with disease, NA not available, FISH fluorescent in situ hybridization, IgH immunoglobulin heavy-chain gene rearrangement, mono monoclonal

MALT lymphomas typically present as a local mass without bone marrow and lymph node involvement in contrast to nodal and splenic MZL. They arise from the marginal zone B-cells and show a spectrum of cellular constituents, from small lymphocytes to monocytoid B-cells to plasma cells. The lymphocytes express B-cell markers (CD19, CD20, and CD79a) and are negative for CD3, CD5, CD10, CD23, and cyclin D1.

In the present case, the morphological, immunohistochemical, and in situ hybridization studies showed that the lymphoma is a low grade MZL, with prominent plasma cell differentiation that is Ig G and kappa light chain restricted. The tumor infiltrated into the underlying brain parenchyma in a perivascular pattern. Small lymphocytic lymphoma/chronic lymphocytic leukemia and mantle-cell lymphomas were excluded by the negative immunostaining for CD5, CD23, and cyclin D1. Follicular lymphoma and lymphoplasmacytic lymphoma were excluded by the morphology, negative CD10, normal serum Ig M, and negative bone marrow examination.

Infectious or inflammatory conditions were ruled out by the demonstration of a dominant clonal population. In situ hybridization showed that the plasma cells are Kappa light chain restricted, while molecular study for IgH gene rearrangement showed a clonal immunoglobulin heavy-chain gene rearrangement.

MALT lymphoma, notably in the lung and gastrointestinal tract, often has a characteristic t(11;18)(q21;q21) translocation. In this translocation, the 3′ end of MALT1 was fused to the 5′ portion of API2, an inhibitor of apoptosis located at 11q21 leading to production of API2-MALT1 fusion transcript [22]. The frequency of this translocation varies depending on the site of origin of the tumor and it was absent or present at very low frequencies in thyroid, skin, liver, and other rare sites [23].

Streubel et al. [24] have identified a second chromosomal aberration involving the MALT1 gene and IgH on 14q32 rather than the API2. Their study showed that 18% (12 out of 66) of the MALT lymphomas were positive for t(14;18)(q32;q21). Interestingly, the anatomical distribution of MALT lymphoma with t(14;18)(q32;q21) was different from that with t(11;18)(q21;q21). The t(14;18) was positive in MALT lymphoma involving ocular adnexa, skin, and the salivary glands, and negative in pulmonary and gastrointestinal MALT lymphoma. MALT lymphomas with different chromosomal abnormalities involving different anatomical sites may indicate different pathogenetic pathways, e.g., the gastric MALT lymphoma is associated with H pylori, whereas those of ocular adnexa, skin, and salivary glands may be associated with other infectious agents or autoimmune diseases.

In the present case, FISH study showed a positive rearrangement of the MALT1 locus. Subsequent studies showed IgH/MALT1 fusion. To our knowledge, this is the first case of primary dural lymphoma of MALT type with a translocation involving IgH and MALT1 genes. The largest series of dural MALT lymphoma reported in the literature was by Tu et al. [25]. They were able to perform FISH study in 12 of the 15 cases. None of their cases showed t(14;18) or t(11;18) translocations. However, 50% of their cases showed trisomy 3 (six out of 12 cases) while our case was negative for this abnormality. Similarly, Kelly et al. [18] have also performed FISH study in their case report and the result was negative for t(11;18) and t(14;18). Additional cases of dural MALT lymphoma need to be studied by FISH to determine the precise frequency of MALT1 rearrangement. Our case suggests that MALT1 translocation play a pathogenetic role in some PCNS MALT lymphoma similar to the other extranodal lymphoma.

In conclusion, we report a rare case of primary dural MALT lymphoma with prominent plasmacytic differentiation and the diagnosis was confirmed by a monoclonal IgH gene rearrangement and a positive MALT1 rearrangement involving IgH and MALT1 on chromosome 14 and 18, respectively.